AGM 2020 Presentation

November 18, 2020May 19, 2021 Alterity Therapeutics

Post navigation

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

AGM 2020 Presentation

Related Posts

Prana Provides Update on IMAGINE Trial and Extension Trial for Alzheimer’s Disease

Prana to present at New York Academy of Science Symposium on November 29th

Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson’s disease clinical trials